Johnson & Johnson (NYSE:JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period. Perhaps the most surprising disappointment of all was that pharmaceutical segment revenue was flat compared with the first half of last year.
